ARKG vs. BBC
Compare and contrast key facts about ARK Genomic Revolution Multi-Sector ETF (ARKG) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).
ARKG and BBC are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. ARKG is an actively managed fund by ARK. It was launched on Oct 31, 2014. BBC is a passively managed fund by Virtus Investment Partners that tracks the performance of the LifeSci Biotechnology Clinical Trials Index. It was launched on Dec 16, 2014.
Performance
ARKG vs. BBC - Performance Comparison
Loading graphics...
ARKG vs. BBC - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ARKG ARK Genomic Revolution Multi-Sector ETF | -8.80% | 23.04% | -28.24% | 16.22% | -53.90% | -33.92% | 180.40% | 44.00% | -1.26% | 46.61% |
BBC Virtus LifeSci Biotech Clinical Trials ETF | 7.95% | 63.77% | -1.11% | -1.80% | -35.13% | -22.31% | 30.32% | 63.81% | -18.29% | 57.85% |
Returns By Period
In the year-to-date period, ARKG achieves a -8.80% return, which is significantly lower than BBC's 7.95% return. Over the past 10 years, ARKG has underperformed BBC with an annualized return of 4.69%, while BBC has yielded a comparatively higher 8.41% annualized return.
ARKG
- 1D
- 6.45%
- 1M
- -11.87%
- YTD
- -8.80%
- 6M
- -4.86%
- 1Y
- 27.26%
- 3Y*
- -4.22%
- 5Y*
- -21.56%
- 10Y*
- 4.69%
BBC
- 1D
- 7.67%
- 1M
- -1.98%
- YTD
- 7.95%
- 6M
- 55.07%
- 1Y
- 141.32%
- 3Y*
- 25.09%
- 5Y*
- -3.63%
- 10Y*
- 8.41%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
ARKG vs. BBC - Expense Ratio Comparison
ARKG has a 0.75% expense ratio, which is lower than BBC's 0.79% expense ratio.
Return for Risk
ARKG vs. BBC — Risk / Return Rank
ARKG
BBC
ARKG vs. BBC - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ARK Genomic Revolution Multi-Sector ETF (ARKG) and Virtus LifeSci Biotech Clinical Trials ETF (BBC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| ARKG | BBC | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.61 | 3.52 | -2.91 |
Sortino ratioReturn per unit of downside risk | 1.19 | 3.86 | -2.67 |
Omega ratioGain probability vs. loss probability | 1.13 | 1.47 | -0.34 |
Calmar ratioReturn relative to maximum drawdown | 0.82 | 6.54 | -5.72 |
Martin ratioReturn relative to average drawdown | 2.22 | 25.10 | -22.88 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| ARKG | BBC | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.61 | 3.52 | -2.91 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.48 | -0.09 | -0.38 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.11 | 0.22 | -0.11 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.08 | 0.12 | -0.04 |
Correlation
The correlation between ARKG and BBC is 0.79, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
ARKG vs. BBC - Dividend Comparison
ARKG has not paid dividends to shareholders, while BBC's dividend yield for the trailing twelve months is around 1.57%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ARKG ARK Genomic Revolution Multi-Sector ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.62% | 0.85% | 3.14% | 0.82% | 1.34% | 0.00% | 0.00% |
BBC Virtus LifeSci Biotech Clinical Trials ETF | 1.57% | 1.70% | 1.00% | 0.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2.09% | 0.00% | 0.51% |
Drawdowns
ARKG vs. BBC - Drawdown Comparison
The maximum ARKG drawdown since its inception was -83.59%, which is greater than BBC's maximum drawdown of -76.85%. Use the drawdown chart below to compare losses from any high point for ARKG and BBC.
Loading graphics...
Drawdown Indicators
| ARKG | BBC | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.59% | -76.85% | -6.74% |
Max Drawdown (1Y)Largest decline over 1 year | -27.51% | -18.03% | -9.48% |
Max Drawdown (5Y)Largest decline over 5 years | -80.18% | -72.58% | -7.60% |
Max Drawdown (10Y)Largest decline over 10 years | -83.59% | -76.85% | -6.74% |
Current DrawdownCurrent decline from peak | -76.36% | -30.71% | -45.65% |
Average DrawdownAverage peak-to-trough decline | -35.30% | -37.30% | +2.00% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.16% | 5.05% | +5.11% |
Volatility
ARKG vs. BBC - Volatility Comparison
ARK Genomic Revolution Multi-Sector ETF (ARKG) and Virtus LifeSci Biotech Clinical Trials ETF (BBC) have volatilities of 13.28% and 13.21%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| ARKG | BBC | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.28% | 13.21% | +0.07% |
Volatility (6M)Calculated over the trailing 6-month period | 31.86% | 26.93% | +4.93% |
Volatility (1Y)Calculated over the trailing 1-year period | 44.94% | 40.92% | +4.02% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 45.37% | 39.30% | +6.07% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 40.94% | 37.86% | +3.08% |